Breast cancer incidence in Spain before, during and after the implementation of screening programmes

Annals of Oncology

Volumn 21, Issue SUPPL.3, 2010, Pages

  Pollan M ^a,b   Michelena, M J ^b,c   Ardanaz, E ^b,d   Izquierdo, A ^e   Sanchez Perez M J ^b,f   Torrella, A ^g   Vicente Arguelles Suarez M ^h   Borras J ⁱ   Franch, P ^j   Jimenez R ^k   Navarro, C ^l   Rabanaque, M J ^m   Ramirez C ^k   Rojas, M D ⁿ   Sainz Miranda M ^o  

^a CARLOS III INSTITUTE OF HEALTH   (Spain)

^b CIBER EPIDEMIOLOGÍA Y SALUD PÚBLICA CIBERESP   (Spain)

^c Gipuzkoa Oncologic Institute   (Spain)

^d INSTITUTO DE SALUD PÚBLICA DE NAVARRA   (Spain)

^e DEPARTMENT OF HEALTH   (Spain)

^f ANDALUSIAN SCHOOL OF PUBLIC HEALTH   (Spain)

^g Directorate General of Public Health   (Spain)

^h Health and Medical Services Authority   (Spain)

ⁱ INSTITUT D INVESTIGACIÓ SANITÀRIA PERE VIRGILI IISPV   (Spain)

^j Mallorca Cancer Registry   (Spain)

^k Health and Social Welfare Authority   (Spain)

^l Health Authority   (Spain)

^m UNIVERSITY OF ZARAGOZA   (Spain)

ⁿ Canary Islands Cancer Registry   (Spain)

^o La Rioja Cancer Registry   (Spain)

more..

Author keywords

Breast cancer incidence; Screening; Time trends

Indexed keywords

ADULT; AGE DISTRIBUTION; ARTICLE; BREAST CANCER; CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CANCER INVASION; CANCER LOCALIZATION; CANCER REGISTRY; CANCER RISK; CANCER SCREENING; CONTROLLED STUDY; FEMALE; HEALTH CARE PLANNING; HEALTH PROGRAM; HUMAN; MAJOR CLINICAL STUDY; PATIENT ASSESSMENT; PATIENT PARTICIPATION; PRIORITY JOURNAL; SPAIN; TREND STUDY; AGED; BREAST TUMOR; COMPARATIVE STUDY; EARLY DIAGNOSIS; INCIDENCE; METHODOLOGY; MIDDLE AGED; TIME;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; EARLY DETECTION OF CANCER; FEMALE; HEALTH PLAN IMPLEMENTATION; HUMANS; INCIDENCE; MIDDLE AGED; SPAIN; TIME FACTORS;

EID: 79951776725     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq095     Document Type: Article

References (35)

1. Parkin DM, Fernandez LM. Use of statistics to assess the global burden of breast cancer. Breast J 2006; 12 Suppl 1: S70-S80.
2. Ravdin PM, Cronin KA, Howlader N et al. The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med 2007; 356: 1670-1674.
3. Kerlikowske K, Miglioretti DL, Buist DS et al. Declines in invasive breast cancer and use of postmenopausal hormone therapy in a screening mammography population. J Natl Cancer Inst 2007; 99: 1335-1339.
4. Jemal A, Ward E, Thun MJ. Recent trends in breast cancer incidence rates by age and tumor characteristics among U.S. women. Breast Cancer Res 2007; 9: R28.
5. Glass AG, Lacey JV, Jr Carreon JD, Hoover RN. Breast cancer incidence, 1980-2006: combined roles of menopausal hormone therapy, screening mammography, and estrogen receptor status. J Natl Cancer Inst 2007; 99: 1152-1161.
6. Kliewer EV, Demers AA, Nugent ZJ. A decline in breast-cancer incidence. N Engl J Med 2007; 357: 509-510.
7. Katalinic A, Rawal R. Decline in breast cancer incidence after decrease in utilisation of hormone replacement therapy. Breast Cancer Res Treat 2008; 107: 427-430.
8. Canfell K, Banks E, Moa AM, Beral V. Decrease in breast cancer incidence following a rapid fall in use of hormone replacement therapy in Australia. Med J Aust 2008; 188: 641-644.
9. Johnston M. Breast cancer drop linked to fall in use of HRT http://www.nzherald.co.nz/health/news/article.cfm?c_id=204&objectid= 10416198 (6 September 2009, date last accessed).
10. Kumle M. Declining breast cancer incidence and decreased HRT use. Lancet 2008; 372: 608-610.
11. Allemand H, Seradour B, Weill A, Ricordeau P. [Decline in breast cancer incidence in 2005 and 2006 in France: a paradoxical trend]. Bull Cancer 2008; 95: 11-15.
12. Ponti A, Rosso S, Zanetti R et al. Re: Breast cancer incidence, 1980-2006: combined roles of menopausal hormone therapy, screening mammography, and estrogen receptor status. J Natl Cancer Inst 2007; 99: 1817-1818.
13. Rossouw JE, Anderson GL, Prentice RL et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 2002; 288: 321-333.
14. Chlebowski RT, Kuller LH, Prentice RL et al. Breast cancer after use of estrogen plus progestin in postmenopausal women. N Engl J Med 2009; 360: 573-587.
15. Pollán M, Pastor-Barriuso R, Ardanaz E et al. Recent changes in breast cancer incidence In Spain, 1980-2004. J Natl Cancer Inst 2009; 101: 1584-1591.
16. Schneider HP. Cross-national study of women's use of hormone replacement therapy (HRT) in Europe. Int J Fertil Womens Med 1997; 42 Suppl 2: 365-375.
17. Benet RM, Carvajal Garcia-Pando A, Garcia DP et al. [Hormonal replacement therapy in Spain]. Med Clin (Barc) 2002; 119: 4-8.
18. McCullagh P, Nelder JA. Generalized Linear Models. London, UK: Chapman & Hall, 1989.
19. Pastor-Barriuso R, Guallar E, Coresh J. Transition models for change-point estimation in logistic regression. Stat Med 2003; 22: 1141-1162.
20. Ascunce N, Ederra M, Barcos A et al. Situació n del cribado de cáncer de mama en Españ a: características y principales resultados de los programas existentes. In Castells X, Sala M, Ascunce N et al. (eds): Descripció n del cribado del cáncer en Españ a. Proyecto DESCRIC. Madrid and Barcelona, Spain: Ministerio de Sanidad y Consumo, Agència d'Avaluació de Tecnologia i Recerca Mèdiques de Cataluñ a 2007; 31-73.
21. Karim-Kos HE, de Vries E, Soerjomataram I et al. Recent trends of cancer in Europe: a combined approach of incidence, survival and mortality for 17 cancer sites since the 1990s. Eur J Cancer 2008; 44: 1345-1389.
22. Robbins AS, Brescianini S, Kelsey JL. Regional differences in known risk factors and the higher incidence of breast cancer in San Francisco. J Natl Cancer Inst 1997; 89: 960-965.
23. Soerjomataram I, Coebergh JW, Louwman MW et al. Does the decrease in hormone replacement therapy also affect breast cancer risk in the Netherlands? J Clin Oncol 2007; 25: 5038-5039.
24. Castelo-Branco C, Ferrer J, Palacios S et al. Spanish post-menopausal women's viewpoints on hormone therapy. Maturitas 2007; 56: 420-428.
25. Ministerio de Sanidad y Consumo and I.N.E. Encuesta Nacional de Salud de España 2006. http://www.msc.es/estadEstudios/estadisticas/encuestaNacional/encuesta20 06.htm.
26. MacMahon B, Cole P. Is the incidence of breast cancer declining? Epidemiology 2008; 19: 268-269.
27. Holford TR, Cronin KA, Mariotto AB, Feuer EJ. Changing patterns in breast cancer incidence trends. J Natl Cancer Inst Monogr 2006: 19-25.
28. Perry N, Broeders M, de Wolf C et al. European guidelines for quality assurance in breast cancer screening and diagnosis, 4th edition. Luxembourg: Office for Official Publications of the European Communities 2006.
29. Esteva M, Ripoll J, Leiva A et al. Determinants of non attendance to mammography program in a region with high voluntary health insurance coverage. BMC Public Health 2008; 8: 387.
30. Anders CK, Johnson R, Litton J et al. Breast cancer before age 40 years. Semin Oncol 2009; 36: 237-249.
31. Bosch X. Investigating the reasons for Spain's falling birth rate. Lancet 1998; 352: 887.
32. Onland-Moret NC, Peeters PH, van Gils CH et al. Age at menarche in relation to adult height: the EPIC study. Am J Epidemiol 2005; 162: 623-632.
33. Cabanes A, Ascunce N, Vidal E et al. Decline in age at menarche among Spanish women born from 1925 to 1962. BMC Public Health 2009 (in press).
34. Colditz GA, Rosner BA. What can be learnt from models of incidence rates? Breast Cancer Res 2006; 8: 208.
35. INE. Anuario Estadístico de Españ a 2009. Instituto Nacional de Estadística 2009.